A D.C. drugmaker has been dealt a major setback in its long-running bid to bring its treatment for a chronic gastrointestinal ...

Gimoti remains the sole proprietary FDA approved treatment for symptoms of diabetic gastroparesisSOLANA BEACH, Calif., Sept.

Vanda Pharmaceuticals Inc. VNDA announced that the FDA issued a complete response letter (CRL) to its new drug application ...

Support for the neurokinin-1 receptor (NK1R) antagonist included a negative phase III trial and a positive phase II study ...

Experts indicate that this rare disorder can lead to various uncomfortable symptoms, including nausea, vomiting, bloating, ...

Vanda Pharmaceuticals (VNDA) stock saw a 9% premarket drop after FDA rejection of its therapy for gastroparesis, citing need ...

Vanda was seeking the health regulator's nod for the drug, tradipitant, to treat symptoms of gastroparesis, a condition ...

Vanda Pharmaceuticals’ shares were down more than 10% at $4.45 pre-market today, as the company provided an unfavorable ...

The FDA has declined to approve Vanda Pharma's tradipitant for delayed gastric emptying (gastroparesis), prompting a furious ...

The Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Vanda Pharmaceuticals regarding the New Drug Application (NDA) for tradipitant for the treatment of gastroparesis.

Gastroparesis is an often overlooked digestive disorder that significantly impacts the quality of life of those affected.

Clearly frustrated by the U.S. FDA’s rejection of tradipitant to treat gastroparesis, Vanda Pharmaceuticals Inc. CEO Mihael Polymeropoulos said the agency is discouraging drug development for the ...